1929-P: Assessing Glycemic Variability by Continuous Glucose Monitoring: Implications for Prediabetes Subtypes and Potential Cardiovascular Risk
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1929-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von PAPANUN MAHAPOL und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Continuous glucose monitoring (CGM) yields information on glycemic variability (GV) which is linked to cardiovascular disease (CVD) in diabetes. However, CGM indicators have been less well studied in prediabetes.
Methods
49 participants underwent a 2-hour oral glucose tolerance test (OGTT) and euglycemic insulin clamp and were subsequently divided into four groups based on their OGTT glucose profile: Normal Glucose Tolerance (NGT, n=6), Isolated Impaired Fasting Glucose (IFG, n=9), Isolated Impaired Glucose Tolerance (IGT, n=4), and Combined IFG and IGT (CGI, n=30). For 5 days, subjects wore a CGM device. Matsuda insulin sensitivity index and Beta-cell function (BCF) (ΔI/ΔG and ΔI/ΔG x Matsuda Index=Disposition Index) were calculated from OGTT.
Results
From CGM, mean glucose was similar in prediabetes and NGT (98±16 vs 98±8 mg/dL). Peak glucose, standard deviation (SD), coefficient of variation (CV), and time above 140 mg/dL (TAR) were all significantly higher in prediabetes than NGT (151 vs 126 mg/dL; 16 vs 10 mg/dL; 0.16 vs 0.10; and 12 vs 0.2% respectively, all p<0.05). Glucose Infusion Rate during the insulin clamp and Disposition Index from OGTT progressively declined in a stepwise fashion from NGT to IFG to IGT to CGI (p<0.01). In the CGI subgroup, the mean CGM glucose correlated negatively with Disposition Index (r= -0.381, p<0.05).
Conclusion
Glycemic variability indices can identify individuals with prediabetes even when mean glucose levels with CGM are normal. Higher CV may provide a metric that these individuals are at higher risk of progression to diabetes. The present findings may inform the design of future studies examining this relationship. Disclosure P. Mahapol: None. A. Merovci: None. S.V. Rosembarque: None. A.A. Hansis-Diarte: None. J.M. Adams: None. E. Cersosimo: None. M. Abdul-Ghani: None. R. Belfort DeAguiar: None. R.A. DeFronzo: Advisory Panel; Ended; AstraZeneca. Research Support; Current; AstraZeneca. Advisory Panel; Current; Novo Nordisk. Research Support; Current; Eli Lilly and Company. Advisory Panel; Current; Corcept Therapeutics. Speaker's Bureau; Current; Corcept Therapeutics. Consultant; Current; Alnylam Pharmaceuticals, Inc. Advisory Panel; Current; Regeneron Pharmaceuticals Inc., Aardvark. A.O. Chavez-Velazquez: Advisory Panel; Ended; Crinetics Pharmaceuticals, Inc. Funding AZ ISSDAPA0002NIH R01 DK024092-37
Zitieren
APA
MAHAPOL, P., MEROVCI, A., ROSEMBARQUE, S. V., HANSIS-DIARTE, A. A., ADAMS, J. M., CERSOSIMO, E., ABDUL-GHANI, M., DEAGUIAR, R. B., DEFRONZO, R. A., & CHAVEZ-VELAZQUEZ, A. O. (2026). 1929-P: Assessing Glycemic Variability by Continuous Glucose Monitoring: Implications for Prediabetes Subtypes and Potential Cardiovascular Risk. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1929-p
Vancouver
MAHAPOL P, MEROVCI A, ROSEMBARQUE SV, HANSIS-DIARTE AA, ADAMS JM, CERSOSIMO E, et al. 1929-P: Assessing Glycemic Variability by Continuous Glucose Monitoring: Implications for Prediabetes Subtypes and Potential Cardiovascular Risk. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1929-p
BibTeX
@article{MAHAPOL2026,
author = {MAHAPOL, PAPANUN and MEROVCI, AURORA and ROSEMBARQUE, SAVIA V. and HANSIS-DIARTE, ANDREA A. and ADAMS, JOHN M. and CERSOSIMO, EUGENIO and ABDUL-GHANI, MUHAMMAD and DEAGUIAR, RENATA BELFORT and DEFRONZO, RALPH A. and CHAVEZ-VELAZQUEZ, ALBERTO O.},
title = {1929-P: Assessing Glycemic Variability by Continuous Glucose Monitoring: Implications for Prediabetes Subtypes and Potential Cardiovascular Risk},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1929-p}
}
EUVIMED